A double blind, randomized placebo controlled study of the efficacy, safety and tolerability of quetiapine fumarate sustained release (Seroquel SRTM) in the treatment of major depression with comorbid fibromyalgia syndrome.

Trial Profile

A double blind, randomized placebo controlled study of the efficacy, safety and tolerability of quetiapine fumarate sustained release (Seroquel SRTM) in the treatment of major depression with comorbid fibromyalgia syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Fibromyalgia; Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2014 Results published in the Arthritis and Rheumatology.
    • 09 Oct 2013 Primary endpoint 'Hamilton-Depression-Rating-Scale' has been met.
    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top